Download  full announcement   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer  and  to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii :   Renalytix AI Plc   (LEI:

Download  full announcement Renalytix AI plc (AIM: RENX), a developer of artificial intelligence (“AI”) enabled clinical diagnostic solutions for kidney disease, announces that it was yesterday notified that on 6 November 2018 the following PDMR undertook a transaction in the ordinary shares of

Download  full announcement NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer  and  to the FCA in Microsoft Word format if possible) i   1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : Renalytix AI PLC 1b.

Download  full announcement Renalytix AI plc (AIM: RENX), a developer of artificial intelligence (“ AI ”) enabled clinical diagnostic solutions for kidney disease, announces the admission of its ordinary shares (“ Ordinary Shares ”) to trading on AIM (“ Admission ”).

Download  full announcement Renalytix AI plc, which develops artificial intelligence (“ AI ”) enabled clinical decision support solutions for kidney disease, announces that, further to the announcement by EKF Diagnostics Holdings plc  (“EKF”)  on 31 October confirming that RenalytixAI’s had

THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY AND RENALYTIX AI PLC TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER ARTICLE 7 OF REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO

THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS DEEMED BY RENALYTIX AI PLC TO CONSTITUTE INSIDE INFORMATION IN RELATION TO THE COMPANY’S QUOTED SECURITIES AS STIPULATED UNDER ARTICLE 7 OF REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE,

Further to the Company’s announcement on 4 July 2018 in relation to Renalytix AI plc (“Renalytix AI”), EKF announces that it intends to undertake further market soundings with institutional and other qualifying potential investors, ahead of a prospective equity Fundraising (defined below) by

The information contained in this announcement is deemed by the company and Renalytix AI Plc to constitute inside information as stipulated under the EU market abuse regulation (596/2014). upon publication of the announcement via a regulatory information service, this information is considered to

Mount Sinai Health System (MSHS) and Renalytix AI Plc today have entered into an exclusive multi-year license and collaboration to commercialize artificial intelligence solutions to improve kidney disease detection, management and treatment for patients with diabetes and other at-risk, large-scale